Hemotoxicity by Prolonged Etoposide Administration to Mice Can Be Prevented by Simultaneous Growth Factor Therapy

Gerald de Haan, Christoph Engel, Bert Dontje, Markus Loeffler, and Willem Nijhof

ABSTRACT

In this study, we determined in vivo interactions between hemopoietic growth factors and etoposide (VP-16) to assess whether normal blood cell production could be maintained during chemotherapy if hemopoietic growth factors were simultaneously administered. Groups of mice were treated for 7 consecutive days with four different doses of VP-16 in combination with three different doses of erythropoietin (EPO) or granulocyte colony-stimulating factor (G-CSF). In total, 12 combinations of VP-16 plus EPO and 12 combinations of VP-16 plus G-CSF were thus evaluated. Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when EPO or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or G-CSF was simultaneously administered with VP-16. These results suggest that in vivo either individual hemopoietic progenitors can become resistant against VP-16-induced cell death by appropriate simultaneous growth factor administration or that the loss of overall cell amplification, induced by VP-16, can be compensated by extra amplification of surviving progenitors. Furthermore, these data indicate that a strict separation in time of cytostatic drug and growth factor treatment is not necessarily the optimal schedule with respect to the reduction of hemotoxicity.

INTRODUCTION

Hemopoietic growth factors are currently being intensively investigated to assess their role in hastening the restoration of reduced peripheral blood cell numbers in chemo- or radiotherapeutic settings. These growth factors are, in the vast majority of cases, administered to patients after they have been treated with anti-neoplastic agents, thus separating the cytotoxic and the cytokinetic therapy in time. This strategy is pursued because very little is known about the in vivo interactions of growth factors are, in the vast majority of cases, administered to patients after they have been treated with anti-neoplastic agents, thus separating the cytotoxic and the cytokinetic therapy in time. This strategy is pursued because very little is known about the in vivo interactions of growth factors with cytostatic drugs. Concern exists about possible enhanced hemotoxicity when growth factors and cytostatic drugs are administered simultaneously, because growth factors may increase the sensitivity of hemopoietic progenitors for cytostatic drugs. Up to now, however, this approach has not been investigated satisfactorily, although there are reasons to believe that the simultaneous administration of specific hemopoietic growth factors and certain cytostatic drugs may well be beneficial in terms of normal blood cell formation, thus allowing chemotherapeutic dose escalation.

Theoretically, it can be argued that a certain dose of a cytostatic drug kills a certain percentage of a specific hemopoietic progenitor cell pool. If a growth factor is administered simultaneously, amplification of the fraction of progenitors which was not killed is increased, which may result in increased peripheral blood cell production. This argument assumes that the sensitivity of the remaining progenitors for the cytostatic drug is not increased by the growth factor.

A second indication for a possible beneficial effect of simultaneous treatment with growth factors and cytostatic drugs comes from the fact that many cytotoxic agents, acting with different molecular mechanisms, induce the appearance of apoptotic characteristics in target cells (1, 2). In addition, it has also been shown that many growth factors prevent dividing cells from apoptosis (3—5). The question arises whether in vivo toxicity, resulting from apoptosis-inducing cytostatic agents, can be prevented by appropriate, apoptosis-preventing growth factors. There are indications from several groups that in vitro this is indeed possible. It has been demonstrated that the induction of apoptosis in leukemic cells, treated with several cytotoxic agents (Adriamycin, 1,3-b-d-arabinofuranosylcytosine, and vincristine), could be prevented by GM-CSF, G-CSF and interleukin 6 (6). Collins et al. (7) analyzed the in vitro effect of a prolonged simultaneous coinoculation of BAF-3 cells with VP-16 or cisplatin and interleukin 3. Interleukin 3 was able to protect cells from apoptotic cell death induced by these drugs (7). If these in vitro results can be extrapolated to in vivo situations, it would open the possibility to protect normal hemopoietic progenitors during chemotherapy.

In the present study, therefore, we assessed normal hemopoietic cell production in mice treated with several doses of VP-16 simultaneously with two widely used growth factors, EPO and G-CSF. It has been shown that continuous administration of VP-16 results in superior responses in patients (8). In the murine system, the VP-16 dose killing 10% of the mice after a 5-day treatment has been shown to be approximately 0.2 mg/day (9). These reports led us to design a multifactorial experiment in which mice were treated with 4 doses of VP-16 (0, 0.05, 0.1, and 0.2 mg/day) for 7 days. Concomitantly, rhEPO or rhG-CSF, each in three doses, was infused. With this approach, we were able to prevent anemia and neutropenia and could increase VP-16 doses significantly without inducing hemotoxicity. By a detailed statistical analysis of the data, we were able to construct equi-response curves of each cellular parameter. These curves illustrate the intricate behavior of the different parameters.

MATERIALS AND METHODS

Mice. Female C57Bl/6 mice, aged 12—16 weeks were used in all experiments.

Growth Factors. Recombinant human EPO, a gift from Boehringer Mannheim (Almere, the Netherlands) was administered at doses of 10 and 25 units/day/mouse. Recombinant human G-CSF, a gift from Agen (Thousand Oaks, CA) was administered at doses of 0.25 and 2.5 µg/day/mouse.

VP-16. VP-16 (etoposide; Vepesid) was obtained from Bristol-Myers Squibb and was administered at doses of 0.05, 0.1, and 0.2 mg/day/mouse.

3 The abbreviations used are: GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte-CSF; EPO, erythropoietin; rh, recombinant human; CFU-E, colony-forming units-erythroid; VP-16, etoposide.
Table 1 Summary of the statistical analysis of the EPO + VP-16 experiment

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>b (EPO)</th>
<th>c (EPO²)</th>
<th>d (VP-16)</th>
<th>e (VP-16²)</th>
<th>f (EPO × VP-16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematocrit</td>
<td>+</td>
<td>NS</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Reticulocytes</td>
<td>NS</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CFU-E/femur</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>CFU-E/spleen</td>
<td>+</td>
<td>NS</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Osmotic Pumps. In order to ensure constant serum levels, growth factors and VP-16 were appropriately diluted and administered by s.c. implanted osmotic pumps (Alza, Palo Alto, CA). EPO and VP-16 were administered by the same pump. G-CSF, however, appeared to be inactivated when mixed with VP-16; therefore, two pumps were implanted in the G-CSF/VP-16 mice.

Cell Suspensions and Assays. Femoral and splenic single cell suspensions were prepared using standard procedures, (11, 12). Hemopoietic progenitors were cultured with the methylcellulose method of Iscove and Sieber (10). CFU-GM/burst-forming unit-erythroid cultures were supplemented with 100 ng/ml recombinant rat stem cell factor (a gift from Amgen), 10 ng/ml recombinant murine GM-CSF (a gift from Behringwerke, Marburg, Germany) and 2 units/ml rhEPO. This resulted in optimal colony formation in our assay. CFU-E cultures were supplemented with 500,000 units/ml EPO. Reticulocytes and neutrophils were counted on, respectively, brilliant crystal blue or May-Grünwald-Giemsa-stained blood smears using light microscopy. The WBC was determined with a Coulter cell analyzer.

Statistical Analysis. Data as given in the figures are the means of 2–4 mice/datapoint. The EPO/VP-16 and G-CSF/VP-16 experiments were designed in a multifactorial way (3 EPO/G-CSF doses × 4 VP-16 doses). The statistical evaluation of this type of experiment involves a regression analysis to determine whether and how much a certain parameter significantly affects the shape of the three-dimensional dose-response surface. This type of analysis is far more powerful than a pairwise comparison of selected datapoints and thereby reduces the number of experimental animals needed to detect significant effects.

We have used this strategy previously in experiments investigating the effects of stem cell factor plus EPO (11) and G-CSF plus EPO (12). In the present study, we could not expect simple linear growth factor dose-response relationships. Therefore the regression model had to be specified in a meaningful way. For both EPO and G-CSF, we have published information showing dose-response saturation characteristics on a logarithmic scale (13, 14). As the regression model analyzes the biological effect (response) of a given G-CSF or EPO dose, these given EPO and G-CSF doses were logarithmically transformed. Thus, EPO doses were coded 0 units = 0, 10 units = 1, and 25 units = 1.4. Similarly, G-CSF doses were coded as 0 μg = 0, 0.25 μg = 1, and 2.5 μg = 2. This coding expresses that the "biological distance" (response) from 0 to 0.25 μg G-CSF is similar as from 0.25 to 2.5 μg G-CSF. The EPO coding analogously acknowledges that the effect from 0 to 10 units EPO is stronger than from 10 to 25 units EPO. This coding protocol is similar as previously published analyses (11, 12).

With the data obtained in the EPO/VP-16 experiment for the number of each cell stage (1), a regression was performed based upon the model: Y = a + b × EPO + c × EPO² + d × VP-16 + e × VP-16² + f × (EPO × VP-16). With the data obtained in the G-CSF/VP-16 experiment, a similar regression was performed, based upon the model: Y = a + b × G-CSF + c × G-CSF² + d × VP-16 + e × VP-16² + f × (G-CSF × VP-16). These models are identical as the ones we have previously published (11, 12). They assess whether: (a) there is a significant linear effect of low EPO/G-CSF doses ("b" term); (b) this linear D/R effect is saturated at higher EPO/G-CSF doses ("c" term); (c) there is a significant effect of low VP-16 doses ("d" term); (d) this linear VP-16 D/R effect reaches saturation at high doses ("e" term); and (e) there is an interaction between EPO and VP-16 ("f" term).

Table 2 Summary of the statistical analysis of the G-CSF + VP-16 experiment

This is a summary of the significance (NS, not significant) and the sign of all coefficient estimates of the regression model which was used for the statistical analysis. Thus it indicates whether a certain cell stage was significantly affected by low G-CSF or VP-16 doses alone (b and c term), whether this effect was saturated at high G-CSF or VP-16 doses alone (c and e term), and whether in the combination of G-CSF and VP-16 significant interaction occurred. As an example, the hematocrit was increased by low EPO doses. At high EPO doses no saturation was observed. VP-16 reduced the hematocrit at low doses, at higher VP-16 doses this linear inhibitory effect was saturated (i.e., had reached its maximum). Furthermore VP-16 had specifically inhibitory effects on EPO-stimulated erythropoiesis.

Table 2

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>b (G-CSF)</th>
<th>c (G-CSF²)</th>
<th>d (VP-16)</th>
<th>e (VP-16²)</th>
<th>f (G-CSF × VP-16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granulocytes/ml</td>
<td>NS</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>NS</td>
</tr>
<tr>
<td>CFU-GM/femur</td>
<td>+</td>
<td>-</td>
<td>NS</td>
<td>+</td>
<td>NS</td>
</tr>
<tr>
<td>CFU-GM/spleen</td>
<td>NS</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

RESULTS

Simultaneous EPO and VP-16 Administration for 7 Days. VP-16 administration during 7 days induced a dose-dependent reticulocytopenia and anemia (Fig. 1). Reticulocytes were undetectable at a dose of 0.1 mg/day or more. This was also reflected in the hematocrit which was maximally reduced to about 37% at a dose of 0.1 mg/day or more. Simultaneous EPO administration dose-dependently increased the number of reticulocytes and the hematocrit at VP-16 doses of 0.05 and 0.1 mg/day. At a VP-16 dose of 0.2 mg/day, however, no protective effect of EPO was observed anymore. The corresponding contour plots, which were created by the regression analysis, illustrate the dose ranges of combined EPO and VP-16 administration which are able to maintain normal values (Fig. 2). It is evident from the slopes of the graphs in Fig. 1 that, although EPO was...
Simultaneous treatment with cytokines and VP-16 administration dose-dependently prevented the neutropenia completely. G-CSF at a dose of 0.25 μg/day, which by itself only had a weak stimulatory effect, was sufficient to normalize neutrophil numbers. G-CSF (2.5 μg/day), which by itself strongly increased neutrophil numbers, induced a mild neutrophilia in combination with all VP-16 doses tested (Fig. 5). Analogous to the erythroid lineage, it is evident that, although G-CSF could protect mice from developing a neutropenia, VP-16 relatively had a stronger inhibiting effect on G-CSF-stimulated than on normal, nonstimulated hemopoiesis (negative interaction term of G-CSF X VP-16; Table 2). Fig. 6 shows at which VP-16 and G-CSF dose ranges normal absolute neutrophil count can be maintained.

To test whether the simultaneous administration of G-CSF and VP-16 was detrimental for myeloid progenitors, CFU-GM numbers in bone marrow and spleen were determined. Fig. 7A demonstrates that CFU-GM numbers in the femur were not decreased by VP-16, neither alone nor in combination with G-CSF. G-CSF itself had opposite effects at different doses; CFU-GM numbers were increased at low G-CSF doses but slightly decreased at high doses. As expected, high doses of G-CSF markedly stimulated splenic granulopoiesis (Fig. 7B). VP-16 alone did not inhibit CFU-GM numbers in the spleen. In

Simultaneous G-CSF and VP-16 Administration for 7 Days. Similar to the effects observed in the erythroid lineage, VP-16 induced a profound neutropenia in 7 days. No dose-dependence in the tested dose range was observed; however, the lowest VP-16 dose of 0.05 mg/day already resulted in peripheral neutrophil numbers reduced to 25% of normal. Increasing the VP-16 dose did not result in enhanced neutropenia. Simultaneous G-CSF admin-

Fig. 1. Effect of a simultaneous administration of EPO and VP-16 for 7 days on reticulocytes (A) and hematocrit (B). Shaded area represents normal range.

Fig. 2. Contour plot, resulting from the regression analysis of the data of Fig. 1, showing equi-response curves of the reticulocytes (A) and hematocrit (B) during combined administration of EPO and VP-16. Shaded area indicates dose ranges at which normal values (± 1 SEM) can be maintained.
DISCUSSION

In this study, we wanted to investigate the in vivo interactions between hemopoietic growth factors and cytostatic drugs. We demonstrate that the anemia and neutropenia induced by a prolonged VP-16 treatment of mice could be prevented by concomitant administration of EPO or G-CSF. This prophylactic use of growth factors did not result in increased myelotoxicity on immature progenitors and allowed dose escalation. VP-16 inhibited erythropoiesis between the CFU-E and the reticulocytes; CFU-E were unaffected, but reticulocytes were absent. Simultaneous EPO administration could normalize the production of reticulocytes from CFU-E at several VP-16 doses. Granulopoiesis was also affected by VP-16, which became apparent in a severely reduced absolute neutrophil count. This was not due, however, to reduced CFU-GM numbers, which remained unaffected. It appears that VP-16 at the doses used inhibits granulopoiesis at some stage between the CFU-GM and the mature granulocytes. Simultaneous G-CSF administration could restore this defective production and was able to prevent neutropenia. Granulopoiesis appeared to be more sensitive to VP-16 than erythropoiesis because, at the lowest VP-16 dose, maximal inhibitory effects were already observed. No effects on platelet count were detected (data not shown).

There are several possibilities which may explain the protection from VP-16-induced hemotoxicity by EPO and G-CSF. The first option takes into account only populations of cells. A certain dose of VP-16 may eliminate a fixed percentage of a specific hemopoietic compartment. If the surviving cells are stimulated by simultaneous EPO or G-CSF therapy, this will increase their amplification and may compensate for the loss of cells induced by VP-16. This implies that the sensitivity for VP-16 of the surviving fraction of cells is not or not strongly increased. In this respect, it is important to consider the in vivo effect of EPO and G-CSF on their target cells. It is unknown to what extent apoptosis regulates in vivo blood cell production (15, 16). If EPO and G-CSF would act primarily by preventing premature cell death, saving these cells by exogenous growth factor administration will rapidly increase their number without necessarily affecting their cycling activity, i.e., their sensitivity for a cell cycle-specific drug. Another mechanism of growth factor activity, however, could be that in vivo they act by increasing the cycling activity of (dormant) cells (17, 18). This would increase the sensitivity of target cells for cell cycle-specific drugs but not necessarily for less S-phase-specific drugs, like VP-16, which can induce apoptosis in quiescent thymocytes (19).
Thus, it appears that the current, strict separation of chemo- and growth factor therapy of cancer patients is not necessarily the optimal way to reduce hemotoxicity. An exception, however, may be leukemic patients; there malignant cells may be protected against chemotherapy (22). The priming of leukemic blast cells with GM-CSF pretreatment before therapy with cytostatic drugs has been studied by several groups, which have reported conflicting results (23—25). The discrepancies, varying from increased complete remission rates (23) to reduced remission rates (25) may reflect the effect of GM-CSF on leukemic cells of different patients (increasing cycling activity versus preventing apoptosis) and the different cytostatic drugs used (6).

The in vivo protection of normal hemopoiesis as we have observed in this study will depend upon the type of growth factors and, more importantly, the type of cytostatic drugs used. Most of the apoptosis-inducing cytostatic drugs, like VP-16, are not very cell cycle specific. Different results may be obtained when growth factors are simultaneously administered with cell cycle-specific drugs, like hydroxyurea or 5-fluorouracil. In fact, it has already been reported that, in humans, the simultaneous use of G-CSF and 5-fluorouracil severely increases myelosuppression (26). Shaffer et al. (27) reported a Phase 1 trial in which the simultaneous use of GM-CSF and VP-16 appeared to result in increased myelotoxicity, compared to VP-16 alone (27). Treatment of mice with stem cell factor, followed by a single injection of 5-fluorouracil, recently has been reported to result in total marrow failure and death (28). Also, different effects may be observed when combinations of growth factors are administered. Recently, we have demonstrated how erythropoiesis and granulopoiesis mutually inhibit each other in splenectomized mice (12). Thus, the present results may differ.

A second option which may explain our findings is that EPO and G-CSF in fact prevent the VP-16-induced apoptotic death of an individual cell. This implies that the sensitivity of a single cell for certain cytostatic drugs can be decreased. There have been several reports showing that this phenomenon exists in myeloid cell lines (6, 7, 20). Several cytostatic drugs which induce apoptosis, like VP-16, are generally thought to specifically inhibit the activity of topoisomerase II. This leads to a stabilization of a drug-topoisomerase II-DNA complex, the so-called cleavable complex (21). It is unknown how this cleavable complex formation ultimately results in apoptotic cell death but it has been suggested that DNA fragmentation is not a direct consequence of VP-16 activity (19). It would be of interest to determine whether growth factors like EPO or G-CSF influence the formation of cleavable complexes or whether these growth factors prevent VP-16 activity via a different molecular mechanism.

The first observations which showed that cells could be protected from DNA damaging agents by hemopoietic growth factors were made with leukemic cells (6, 7). We show in this study that these effects can be extrapolated to normal in vivo hemopoiesis.
quantitatively when EPO plus G-CSF are simultaneously administered. These data illustrate the importance of clarifying the underlying mechanisms of the protective effects in order to select beneficial combinations and timing schedules of growth factors and cytostatic drugs.

REFERENCES


Fig. 8. Contour plot, resulting from the regression analysis of the data of Fig. 7, showing equi-response curves of CFU-GM/femur (A) and spleen (B) during combined administration of EPO and VP-16. Shaded area indicates dose ranges at which normal values (±1 SEM) can be maintained.
Hemotoxicity by Prolonged Etoposide Administration to Mice Can Be Prevented by Simultaneous Growth Factor Therapy

Gerald de Haan, Christoph Engel, Bert Dontje, et al.


**Updated version**  Access the most recent version of this article at: [http://cancerres.aacrjournals.org/content/55/2/324](http://cancerres.aacrjournals.org/content/55/2/324)

**E-mail alerts**  Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.